HEART FAILURE
Lack of evidence for peripheral alpha1- adrenoceptor blockade during long-term treatment of heart failure with carvedilol
Toshihiko Kubo, MD, PhDa,
Eduardo R. Azevedo, MDa,
Gary E. Newton, MD, FACCa,
John D. Parker, MD, FACCa and
John S. Floras, MD, DPhil, FACC*,a
a Division of Cardiology, Mount Sinai Hospital and the University of Toronto, Toronto, Canada
Manuscript received April 6, 2001;
revised manuscript received June 21, 2001,
accepted July 13, 2001.
* Reprint requests and correspondence to: Dr. John S. Floras, 600 University Avenue, Suite 1614, Toronto, Ontario M5G 1X5, Canada john.floras{at}utoronto.ca
OBJECTIVES
The purpose of this study was to determine whether carvedilols alpha1-adrenoceptor antagonism persists during long-term therapy of patients with congestive heart failure (CHF).
BACKGROUND
Carvedilol and metoprolol differ in that carvedilol also antagonizes beta2- and alpha1-adrenoceptors. We hypothesized that in contrast to metoprolol, carvedilol would increase calf vascular conductance (CVC), blunt neurally mediated vasoconstriction and attenuate neuroeffector transfer function gain.
METHODS
We randomized 36 patients with CHF (age 55 ± 1 years, ejection fraction 19 ± 1%, means ± SE) to either drug. Blood pressure (BP), heart rate, muscle sympathetic nerve activity (MSNA) and CVC were assessed before and after four months of treatment. The variability of BP and MSNA was determined using fast Fourier transformation.
RESULTS
Paired data were obtained in 23 (carvedilol, 13; metoprolol, 10) subjects. Both beta-blockers decreased heart rate, but neither affected mean BP or CVC (carvedilol: 0.016 ± 0.002 to 0.018 ± 0.003 U; metoprolol: 0.020 ± 0.002 to 0.020 ± 0.004 U). Isometric handgrip exercise (30% of maximum) increased heart rate, mean BP and MSNA. The calf vasoconstrictor response to handgrip exercise was not affected by carvedilol (from 16 ± 6 resistance U to 25 ± 10 resistance U, NS). The gain of the transfer of oscillations in MSNA into BP under resting conditions was not attenuated by carvedilol.
CONCLUSIONS
Carvedilol did not increase CVC, blunt the calf vasoconstrictor response to handgrip or attenuate the gain of the neuroeffector transfer function, indicating the absence of functionally important peripheral alpha1-adrenoceptor antagonism during long-term treatment of CHF.
|
Abbreviations and Acronyms
| | ANOVA | = analysis of variance | | BP | = blood pressure | | CBF | = calf blood flow | | CHF | = congestive heart failure | | CVC | = calf vascular conductance | | CVR | = calf vascular resistance | | ECG | = electrocardiogram | | HF | = high frequency | | LF | = low frequency | | MSNA | = muscle sympathetic nerve activity | | VLF | = very low frequency |
|
This article has been cited by other articles:

|
 |

|
 |
 
P. A. Sperandio, A. Borghi-Silva, A. Barroco, L. E. Nery, D. R. Almeida, and J. A. Neder
Microvascular oxygen delivery-to-utilization mismatch at the onset of heavy-intensity exercise in optimally treated patients with CHF
Am J Physiol Heart Circ Physiol,
November 1, 2009;
297(5):
H1720 - H1728.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J S Floras
Should sleep apnoea be a specific target of therapy in chronic heart failure?
Heart,
July 1, 2009;
95(13):
1041 - 1046.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Woodcock, X.-J. Du, M. E. Reichelt, and R. M. Graham
Cardiac {alpha}1-adrenergic drive in pathological remodelling
Cardiovasc Res,
February 1, 2008;
77(3):
452 - 462.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-a. Koshimizu, G. Tsujimoto, A. Hirasawa, Y. Kitagawa, and A. Tanoue
Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human {alpha}1D- and {alpha}1B-adrenergic receptors
Cardiovasc Res,
September 1, 2004;
63(4):
662 - 672.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Task Force Members, J. Lopez-Sendo, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al.
Expert consensus document on {beta}-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology
Eur. Heart J.,
August 1, 2004;
25(15):
1341 - 1362.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kindermann, C. Maack, S. Schaller, N. Finkler, K. I. Schmidt, S. Laer, H. Wuttke, H.-J. Schafers, and M. Bohm
Carvedilol but Not Metoprolol Reduces {beta}-Adrenergic Responsiveness After Complete Elimination From Plasma In Vivo
Circulation,
June 29, 2004;
109(25):
3182 - 3190.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. N. Doughty, G. A. Whalley, H. A. Walsh, G. D. Gamble, J. Lopez-Sendon, N. Sharpe, and on behalf of the CAPRICORN Echo Substudy Investiga
Effects of Carvedilol on Left Ventricular Remodeling After Acute Myocardial Infarction: The CAPRICORN Echo Substudy
Circulation,
January 20, 2004;
109(2):
201 - 206.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Hryniewicz, A. S. Androne, A. Hudaihed, and S. D. Katz
Comparative Effects of Carvedilol and Metoprolol on Regional Vascular Responses to Adrenergic Stimuli in Normal Subjects and Patients With Chronic Heart Failure
Circulation,
August 26, 2003;
108(8):
971 - 976.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Vittorio, C. C. Lang, S. D. Katz, M. Packer, D. M. Mancini, and U. P. Jorde
Vasopressor Response to Angiotensin II Infusion in Patients With Chronic Heart Failure Receiving {beta}-Blockers
Circulation,
January 21, 2003;
107(2):
290 - 293.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Floras
The "Unsympathetic" Nervous System of Heart Failure
Circulation,
April 16, 2002;
105(15):
1753 - 1755.
[Full Text]
[PDF]
|
 |
|
|